(TheNewswire)
Toronto, Ontario - The Newswire - September 25 , 2020 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT) is pleased to announce that, subject to TSXV approval, it has engaged San Diego T orrey Hills Capital, Inc. ("Torrey Hills Capital"), a Rancho Santa Fe, California based investor relations firm, to provide market awareness and investor relations services to the Company in compliance with TSXV policies. Cliff Mastricola is the principal of Torrey Hills Capital and will be responsible for activities related to Ventripoint.
Torrey Hills Capital is a leading investor and financial public relations firm specializing in small and microcap companies. Torrey Hills Capital will increase awareness about Ventripoint through its established relationships with investment professionals, investment advisors, and money managers focused on the microcap market space. This will allow the Company to build and maintain an informed investor audience in both the U.S. and Canadian marketplaces.
Torrey Hills Capital will receive US$ 5 ,000 per month during the term of the agreement. After an initial one month term, the agreement will be automatically extended, subject to a 15 -day termination notice by either party. Ventripoint has also agreed to a one-time grant of 3 00,000 incentive stock options (the "Options") exercisable at a price of C$0. 10 per share exercisable for a period of three years. The Options will be subject to the terms of the Company's stock option plan and will vest in accordance with the provisions therein and the policies of the TSX-V.
Torrey Hills Capital currently has no direct or indirect interest in the securities of Ventripoint , or any right or intent to acquire such an interest except pursuant to the exercise of the above referenced Options.
The appointment of Torrey Hills Capital as an investor relations consultant of Ventripoint and the granting of the Options remain subject to regulatory acceptance of applicable filings with the TSX-V.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
About Torrey Hills Capital
Torrey Hills Capital was formed in 1998 and is headquartered in Rancho Santa Fe, California. The team of professionals offers experience and expertise in investor relations, corporate communications, non-deal road shows, and market support activities. Torrey Hills Capital specializes in the development and marketing of emerging growth companies which trade in the United States (NYSE, AMEX, and OTC) and in Canada (TSX, TSX-V, and CSE). Marketing activities articulate key investment attributes, strategic direction, and financial expectations, which combine to ensure that client market value fully reflects past achievements and future opportunities. Further information is available at www.torreyhillscapital.com
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Mr . Peter Weichler, Director
Email :peter@weichler.ca
Or
Mr. Clay Chase
Email: cc@sdthc.com
Phone: 858-456-7300
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Copyright (c) 2020 TheNewswire - All rights reserved.